1. United States Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
WELSIS CORP.

WELSIS CORP.

OOTC:WLSS
0.60
USD
-1.89
(-75.90%)
-0.02EPS
6.61MMarket Cap
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
0.01
- -
- -
- -
Basic EPS, GAAP
-0.02
-0.01
-0.01
-0.02
-0.02
Free Cash Flow per Basic Share
-0.03
-0.02
-0.01
-0.02
-0.02
Dividend per Share
- -
- -
- -
- -
- -
Book Value per Share
-0.03
-0.04
-0.03
-0.05
-0.06
Tangible Book Value per Share
-0.04
-0.05
-0.03
-0.05
-0.06
Basic Weighted Avg Shares
3
3
3
3
3
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
Operating Margin (%)
- -
-119.97
-2,894.9
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-132.91
-1,234.15
- -
- -
Working Capital
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -

Capital Structure

USD

•

in mil. unless spec.
Jun'25
Sep'25
Dec'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3
3
3
Market Capitalization
8
10
7

Working Capital

USD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
67.7%
Free Cash Flow
- -
- -
66.61%
Net Income, GAAP
- -
- -
145.88%
Sales/Revenue/Turnover
- -
- -
-100%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.01
-0.01
-0.01
-0.01
2025
-0.01
- -
- -
-0.01
-0.02
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Boon Kit Kwok
Full Time Employees
1
Sector
Health services
Industry
Medical/Nursing services
Address
701 E Cathedral Road Philadelphia PA United States 19128
IPO Date
Jun 7, 2023
CIK
0001887912
Website
welsis.com
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Mobile-health Network Solutions (NASDAQ:MNDR)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
Welsis Corp. (WLSS) is a development-stage company providing online psychological help services, also known as teletherapy or telepsychology, through a platform offering counseling and psychological support for adolescents from age 14 and adults, for men and women; therapy for individuals, couples, and families; and a cryptocurrency exchange platform via TokenTraders.net that enables users to exchange and trade digital assets. The company operates in the healthcare services industry, specifically health information and medical/nursing services segments, with a primary focus on virtual therapy solutions delivered by licensed therapists. Incorporated in Wyoming on August 16, 2021, and headquartered at 701 E. Cathedral Road, Suite 45 PMB 405, Philadelphia, Pennsylvania 19128, United States, Welsis maintains a minimal operational footprint with one employee and conducts activities in the United States and Serbia. In recent developments, Welsis has transitioned into the cryptocurrency and blockchain sector by launching TokenTraders.net, expanding beyond its core teletherapy offerings to include crypto trading capabilities, as noted in its fiscal 2024 quarterly filings. The company reported minimal revenue of $2,000 for fiscal year 2024 ended September 30, alongside a reduced net loss of $24,683 compared to prior periods, while financing operations through convertible notes amid ongoing working capital challenges. No significant acquisitions, partnerships, funding rounds, or major strategic alliances have been publicly disclosed in the last 1-2 years, with focus remaining on development-stage operations and SEC compliance through periodic 10-Q and 10-K filings into 2025.